CMMB
Chemomab Therapeutics Ltd. [CMMB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CMMB Stock Summary
Top 10 Correlated ETFs
CMMB
Top 10 Correlated Stocks
CMMB
In the News
CMMB Financial details
Company Rating
-
Market Cap
10.93M
Income
-24.24M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.18
Forward P/E
-
PEG
0.14
P/S
-
P/B
0.27
P/C
-
P/FCF
-0.26
Quick Ratio
4.05
Current Ratio
4.06
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-15.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.59%
-
-
-
-
SMA20
8.7%
SMA50
-36.55%
SMA100
-26.47%
Inst Own
-
Inst Trans
-
ROA
-115%
ROE
-102%
ROC
-1.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.42-1.89
52W High
-
52W Low
-
RSI
58.52
Rel Volume
0.25
Avg Volume
232.3K
Volume
58.62K
Perf Week
16.38%
Perf Month
-6.25%
Perf Quarter
-6.25%
Perf Half Y
-11.76%
-
-
-
-
Beta
-0.044
-
-
Volatility
0.06%, 0.12%
Prev Close
5.47%
Price
1.35
Change
0%
Company Profile
- Volume Average 232.3K
- Market Capitalization 10.93M
- Employee 20
- CEO Dr. Adi Mor George Ph.D.
- Headquarters Tel Aviv,IL
- IPO Date 2019-02-12
-
Website
https://www.chemomab.com 
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
